flutikason cipla 125 mikrog/ dose
cipla europe nv - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose
flutikason cipla 250 mikrog/ dose
cipla europe nv - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 250 mikrog/ dose
salmeterol/fluticasone neutec 50 mikrog / 100 mikrog
neutec inhaler ireland limited - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 100 mikrog
salmeterol/fluticasone neutec 50 mikrog / 250 mikrog
neutec inhaler ireland limited - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 250 mikrog
salmeterol/fluticasone cipla 25 mikrog / 125 mikrog
cipla europe nv - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 125 mikrog
salmeterol/fluticasone cipla 25 mikrog / 250 mikrog
cipla europe nv - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 250 mikrog
salmeterol/fluticasone neutec 50 mikrog / 500 mikrog
neutec inhaler ireland limited - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 500 mikrog
flutikason teva 50 mikrog
teva b.v. - flutikasonpropionat - nesespray, suspensjon - 50 mikrog
flurhin 50 mikrog/ dose
2care4 generics aps - flutikasonpropionat - nesespray, suspensjon - 50 mikrog/ dose
seffalair spiromax
teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - legemidler for obstruktive sykdommer i luftveiene, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.